Silence-Intradigm Deal is Only Year-End Noise on Quiet RNAi Front
The only RNAi-focused merger of the year so far weds two minor players trying to build a much-needed drug delivery platform.
The only RNAi-focused merger of the year so far weds two minor players trying to build a much-needed drug delivery platform.